Difference between revisions of "Committee Procedures"
Jump to navigation
Jump to search
Line 1: | Line 1: | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Committee Leadership== | ==Committee Leadership== | ||
− | * Coordinating Committees, Biomarker Committees and Task Forces are encouraged to have 2 or 3 leaders who are preferably drawn from diverse backgrounds (Researchers, Clinicians, Physicists, Vendors, Regulators, etc.). If not possible, some concentration | + | * Coordinating Committees, Biomarker Committees and Task Forces are encouraged to have 2 or 3 leaders who are preferably drawn from diverse backgrounds (Researchers, Clinicians, Physicists, Vendors, Regulators, etc.). If not possible, committees are permitted to have some concentration but should discuss plans to expand stakeholder representation at least annually. |
==Decision Making== | ==Decision Making== | ||
Line 35: | Line 11: | ||
** Meeting attendee names and vote outcome will be recorded in minutes. | ** Meeting attendee names and vote outcome will be recorded in minutes. | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==See Also== | ==See Also== | ||
* [[Committees|QIBA Committees]] | * [[Committees|QIBA Committees]] |
Revision as of 00:31, 7 March 2018
Committee Leadership
- Coordinating Committees, Biomarker Committees and Task Forces are encouraged to have 2 or 3 leaders who are preferably drawn from diverse backgrounds (Researchers, Clinicians, Physicists, Vendors, Regulators, etc.). If not possible, committees are permitted to have some concentration but should discuss plans to expand stakeholder representation at least annually.
Decision Making
- Goal: group consensus and imaging community input and endorsement on major decisions.
- Recorded vote required for procedural decisions
- Key group decisions, such as public dissemination of documents, are subject to approval by Modality Coordinating Committees
- Majority of participating members passes
- Negative votes must be discussed
- For recorded votes:
- Meeting attendee names and vote outcome will be recorded in minutes.